



DOCKET NO.: AREN11.US12.CON

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: **Chen W. Liaw and I-Lin Lin**

Confirmation No.: **5835**

Serial No.: **10/782,596**

Art Unit No.: **1646**

Filing Date: **February 19, 2004**

Examiner: **Ruixiang Li**

For: **NUCLEIC ACID ENCODING HUMAN G PROTEIN-COUPLED RECEPTOR**

Customer No.: **35133**

EXPRESS MAIL INFORMATION
EXPRESS MAIL LABEL NO: EV146 601 579US
DATE OF DEPOSIT: December 20, 2005

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08b, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ before the mailing date of a first Office Action on the merits.
- ☒ after the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114, but before the

mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

and

☒ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

☐ No fee is owed by the applicant(s).

☐ In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.

☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).

☒ A copy of the references listed on the attached PTO Form SB/08b, formerly known as PTO Form 1449 is enclosed herewith,

EXCEPT THAT:

☐ In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.

☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

☒ Copies of references **A13 and A15-A18**, listed on the attached PTO Form SB/08A and PTO Form SB/08B, were previously cited by or submitted to the U.S. Patent and Trademark Office in parent **Application Serial No. 09/875,076 filed June 6, 2001**.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Pursuant to Fed. Reg. Vol. 69, No. 182, dated September 21, 2004, copies of U.S. Patents and U.S. Patent Publications need not be submitted as part of a Supplemental Information Disclosure Statement.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- ☐ The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in § 1.56(c) more than 30 days prior to the filing of the Supplemental Information Disclosure Statement.

Fees

- ☐ No Fee is owed by the applicant(s).
- ☒ The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is authorized to be charged to Deposit Account No. 50-1275.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).


Respectfully submitted



Michael A. Patané
Registration No. 42,982

Dated: December 20, 2005

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-6966 – Telephone
(215) 701-2080 - Facsimile



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

<i>Application Number</i>	10/782,596
<i>Filing Date</i>	February 19, 2004
<i>First Named Inventor</i>	Chen W. Liaw, et al.
<i>Art Unit</i>	1646
<i>Examiner Name</i>	Ruixiang Li
<i>Attorney Docket Number</i>	AREN11.US12.CON

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	A12	CA 2 362 906	08-31-2000	Synaptic Pharmaceutical Corp.		
	A13	EP 1 092 727	04-18-2001	Pfizer Ltd.		
	A14	WO 00/22131	04-20-2000	Arena Pharm Inc.		
	A15	WO 00/50562	08-31-2000	Synaptic Pharma Corp.		
	A16	WO 01/32864	05-10-2001	Merck Patent		
	A17	WO 01/36473	05-25-2001	Upjohn Co.		
	A18	WO 01/42288	06-14-2001	Incyte Genomics Inc.		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/782,596	
			Filing Date	February 19, 2004	
			First Named Inventor	Chen W. Liaw, et al.	
			Art Unit	1646	
			Examiner Name	Ruixiang Li	
Sheet	2	of	2	Attorney Docket Number	AREN11.US12.CON

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A19	BROUN, P., ET AL., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," <i>Science</i> , 282 :1315-1317, (November 13, 1998)	
	A20	FEHMANN, H.-C., ET AL., "Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide," <i>Endocrine Reviews</i> , 16 (3):390-410, (1995)	
	A21	LEURS, R., ET AL., "Agonist-independent regulation of constitutively active G-protein-coupled receptors," <i>TIBS</i> , 23 :418-422, (November, 1998)	
	A22	MURDOCH, C. and FINN, A., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> , 95 (10):3032-3043, (May 15, 2000)	
	A23	NG, D.H.W., ET AL., "Point Mutation in the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," <i>Biochemical and Biophysical Research Communications</i> , 206 (1):302-309, (January 5, 1995)	
	A24	PAUWELS, P.J. and WURCH, T., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors," <i>Molecular Neurobiology</i> , 17 :109-135, (1998)	
	A25	REN, Q., ET AL., "Constitutively Active Mutants of the α_2 -Adrenergic Receptor," <i>The Journal of Biological Chemistry</i> , 268 (22):16483-16487, (1993)	
	A26	SKOLNICK, J., ET AL., "Structural genomics and its importance for gene function analysis," <i>Nature Biotechnology</i> , 18 :283-287, (March, 2000)	
	A27	THORENS, B., "Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1," <i>Proc. Natl. Acad. Sci.</i> , 89 :8641-8645, (September, 1992)	
	A28	WATSON, S. and ARKINSTALL, S., <i>The G-Protein Linked Receptor Facts Book</i> , pp. 223-230, (1994)	
	A29	Genebank Accession No. AL035423, version AL035423.4 GI:4467309, "Homo sapiens chromosome X clone 2013," accessed by PTO on 4/28/2004, (February 27, 1999)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.